Tirosina quinasa / adaptadores
Los inhibidores de tirosina quinasa y adaptadores son compuestos que se dirigen a las tirosina quinasas y sus proteínas adaptadoras asociadas, las cuales desempeñan roles cruciales en la señalización celular, el crecimiento y la diferenciación. Estos inhibidores son herramientas esenciales en la investigación del cáncer, ya que muchas tirosina quinasas están involucradas en las vías de señalización que impulsan el crecimiento tumoral y la metástasis. Al inhibir las tirosina quinasas, estos compuestos pueden bloquear cascadas de señalización críticas, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades que implican una señalización celular anormal. En CymitQuimica, ofrecemos una amplia gama de inhibidores de tirosina quinasa y adaptadores de alta calidad para apoyar su investigación en oncología, biología molecular y desarrollo de terapias dirigidas.
Subcategorías de "Tirosina quinasa / adaptadores"
- ALK(112 productos)
- CSF-1R(42 productos)
- EGFR(572 productos)
- Receptor de efrina(23 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- HER(5 productos)
- Hck(3 productos)
- IGF-1R(88 productos)
- PDGFR(126 productos)
- PYK2(7 productos)
- Src(79 productos)
- Receptor TAM(32 productos)
- Tie-2(20 productos)
- Receptor de Trk(59 productos)
- Tirosina quinasas(26 productos)
- VEGFR(268 productos)
- c-Fms(108 productos)
- c-Kit(101 productos)
- c-Met / HGFR(128 productos)
- c-RET(51 productos)
Mostrar 13 subcategorías más
Se han encontrado 1370 productos de "Tirosina quinasa / adaptadores"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Forma y color:SolidPeso molecular:339.78c-Fms-IN-2
CAS:<p>c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).</p>Fórmula:C19H21N3O3Pureza:99.56%Forma y color:SolidPeso molecular:339.39Rp-cAMPS triethylammonium salt
CAS:<p>Rp-cAMPS triethylammonium salt is a competitive inhibitor of cAMP-dependent protein kinase I and II.</p>Fórmula:C16H27N6O5PSPureza:98%Forma y color:SolidPeso molecular:446.46EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Fórmula:C25H25ClFN5O4Forma y color:SolidPeso molecular:513.95PF-4618433
CAS:<p>PF-4618433 is a selective PYK2 inhibitor with osteogenic activity.</p>Fórmula:C24H27N7O2Pureza:99.95%Forma y color:SolidPeso molecular:445.52Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49Infigratinib phosphate
CAS:<p>Infigratinib phosphate (BGJ-398 phosphate) is an effective inhibitor of the FGFR family (IC50: 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and</p>Fórmula:C26H34Cl2N7O7PPureza:99.24% - 99.6%Forma y color:SolidPeso molecular:658.47CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Forma y color:SolidPeso molecular:329.35IACS-9439
CAS:<p>IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM.</p>Fórmula:C23H26ClN7O3SPureza:98%Forma y color:SolidPeso molecular:516.02RO9021
CAS:<p>RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).</p>Fórmula:C18H25N7OPureza:97.19%Forma y color:SolidPeso molecular:355.44Sotuletinib dihydrochloride
CAS:<p>Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM.</p>Fórmula:C20H24Cl2N4O3SPureza:98%Forma y color:SolidPeso molecular:471.4OXSI-2
CAS:<p>OXSI-2 (Syk Inhibitor) is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM.</p>Fórmula:C18H15N3O3SPureza:98%Forma y color:Dark Orange SolidPeso molecular:353.39JNJ-64264681
CAS:<p>JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C27H30N6O3SPureza:98%Forma y color:SolidPeso molecular:518.63Protein kinase inhibitor 5
CAS:<p>Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, demonstrating an IC50 of 1.8 nM, and effectively suppresses cell viability [1].</p>Fórmula:C29H31F2N7OPureza:98%Forma y color:SolidPeso molecular:531.6ER-27319
CAS:<p>ER-27319, an acridone derivative, serves as a potent and selective inhibitor of spleen tyrosine kinase (SYK), effectively impeding both the tyrosine</p>Fórmula:C20H22N2O5Pureza:98%Forma y color:SolidPeso molecular:370.4CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Fórmula:C34H41FN6O5Pureza:99.20%Forma y color:SolidPeso molecular:632.72SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96DMH4
CAS:<p>DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 µM.</p>Fórmula:C24H24N4O2Pureza:99.58%Forma y color:SolidPeso molecular:400.47c-Kit-IN-2
CAS:<p>c-Kit-IN-2 is a c-KIT inhibitor (IC50: 82 nM), shows superior antiproliferative activities against all the three GIST cell lines, GIST430, GIST882, and GIST48 (</p>Fórmula:C25H29N9O2SPureza:98%Forma y color:SolidPeso molecular:519.62Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:619.7Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12MMPP
CAS:<p>MMPP is a VEGFR2 inhibitor with anti-inflammatory activity, inhibits STAT3 , inhibits angiogenesis, and can be used to alleviate myocardial injury.</p>Fórmula:C17H18O3Pureza:99.31% - 99.83%Forma y color:SolidPeso molecular:270.32EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45Syk-IN-3
CAS:<p>Syk-IN-3 is a Syk inhibitor with potential anti-inflammatory and anticancer activity and can be used to study immune dysregulation.</p>Fórmula:C24H28N4O3SPureza:97.29% - >99.99%Forma y color:SolidPeso molecular:452.57PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.76LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65c-Fms-IN-8
CAS:<p>c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.</p>Fórmula:C27H30N2O5Pureza:98%Forma y color:SolidPeso molecular:462.54c-Fms-IN-1
CAS:<p>c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).</p>Fórmula:C22H27N5O2Pureza:99.94%Forma y color:SolidPeso molecular:393.48EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51JAK-IN-21
CAS:<p>JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.</p>Fórmula:C19H16N8OPureza:99.75%Forma y color:SolidPeso molecular:372.38NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39c-Fms-IN-9
CAS:<p>c-Fms-IN-9 inhibits c-FMS/uFMS and uKIT with IC50 <0.01μM and 0.1-1μM, from patent WO2014145023A1.</p>Fórmula:C21H23N7O2Pureza:98%Forma y color:SolidPeso molecular:405.45Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Forma y color:SolidPeso molecular:565.06EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33c-Kit-IN-3
CAS:<p>c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).</p>Fórmula:C26H20ClF3N2O4Pureza:99.94%Forma y color:SolidPeso molecular:516.9Ansornitinib
CAS:<p>Ansornitinib (ANG-3070) is a KDR and PDGF receptor inhibitor with antifibrotic activity for the study of diseases caused by abnormal or excessive fibrosis.</p>Fórmula:C30H32N6O4Forma y color:SolidPeso molecular:540.61FGFR2-IN-1
CAS:<p>FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used to study FGFR2-associated cancers.</p>Fórmula:C22H19N3O2Pureza:98.71%Forma y color:SolidPeso molecular:357.41GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Fórmula:C23H25N7O2Pureza:99.9%Forma y color:SolidPeso molecular:431.49MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Forma y color:SolidPeso molecular:268.23AMG-Tie2-1
CAS:<p>AMG-Tie2-1 is a Tie2 and VEGFR2 inhibitor with anticancer and antitumor activity for the study of cardiovascular disease and cancer.</p>Fórmula:C25H20F3N5O2Pureza:98.9%Forma y color:SolidPeso molecular:479.45EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Fórmula:C31H29FN4O2Pureza:98%Forma y color:SolidPeso molecular:508.59JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6Spebrutinib besylate
CAS:<p>Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).</p>Fórmula:C28H28FN5O6SPureza:98%Forma y color:SolidPeso molecular:581.62Sovleplenib
CAS:<p>Sovleplenib (HMPL-523), oral SYK inhibitor, IC50 25 nM, targets tumors & ITP studies.</p>Fórmula:C24H30N6O3SPureza:99.71%Forma y color:SolidPeso molecular:482.6EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Fórmula:C26H34N6O3SPureza:98.82% - 99.81%Forma y color:SolidPeso molecular:510.65PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Forma y color:SolidPeso molecular:441.27(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32CHMFL-BTK-01
CAS:<p>CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.</p>Fórmula:C38H41N5O5Pureza:98%Forma y color:SolidPeso molecular:647.76EML4-ALK kinase inhibitor 1
CAS:<p>Potent oral EML4-ALK inhibitor with a 1 nM IC50.</p>Fórmula:C31H48N8O3Pureza:99.62%Forma y color:SolidPeso molecular:580.76EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Forma y color:SolidPeso molecular:562.54GSK-2250665A
CAS:<p>GSK-2250665A is an (Itk) inhibitor (pKi 9.2) with selectivity over Aurora B and Btk, inhibiting IFNγ in PBMCs for T-cell signaling studies.</p>Fórmula:C26H29N5OSPureza:98%Forma y color:SolidPeso molecular:459.61EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SForma y color:SolidPeso molecular:711.68EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68ALK-IN-5
CAS:<p>ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK, IC50: 2.9 nM).</p>Fórmula:C24H25FN6O3Pureza:98%Forma y color:SolidPeso molecular:464.49Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidBAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Forma y color:SolidPeso molecular:265.26DDR-TRK-1
CAS:<p>DDR-TRK-1 is a selective discoid domain receptor 1 (DDR1) inhibitor with IC50 value of 9.4 nM. DDR-TRK-1 also inhibits the TRK family.</p>Fórmula:C26H23F3N6OPureza:99.63%Forma y color:SolidPeso molecular:492.5Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Fórmula:C13H8N4OPureza:97.01%Forma y color:SolidPeso molecular:236.23CSF1R-IN-7
CAS:<p>CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for treatment of diseases associated with microglia-mediated neuroinflammation.</p>Fórmula:C22H22N6O3Pureza:99.41% - 99.93%Forma y color:SolidPeso molecular:418.45c-Fms-IN-6
CAS:<p>c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).</p>Fórmula:C22H25N7O2Pureza:98%Forma y color:SolidPeso molecular:419.48DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Fórmula:C32H31N5O3Pureza:99.25%Forma y color:SolidPeso molecular:533.62AC710 Mesylate
CAS:<p>AC710 Mesylate is a potent PDGFR inhibitor (Kds: 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ).</p>Fórmula:C32H46N6O7SPureza:98%Forma y color:SolidPeso molecular:658.81JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44SSR128129E free acid
CAS:<p>SSR128129E free acid is an orally available and allosteric inhibitor of FGFR(IC50 of 1.9 μM for FGFR1).</p>Fórmula:C18H16N2O4Pureza:98%Forma y color:SolidPeso molecular:324.33ALK2-IN-2
CAS:<p>ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) (IC50: 9 nM), inhibiting ALK2 700-fold more than ALK3.</p>Fórmula:C28H27N5O2SPureza:99.55%Forma y color:SolidPeso molecular:497.61Lanraplenib monosuccinate
CAS:<p>Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.</p>Fórmula:C27H31N9O5Pureza:98%Forma y color:SolidPeso molecular:561.59EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Fórmula:C19H17ClFN3O4Pureza:98%Forma y color:SolidPeso molecular:405.81CE-245677 mesylate
CAS:<p>CE-245677 mesylate is a selective Tie2 kinase inhibitor with oral activity and potential anti-tumor effects, useful in pain research.</p>Fórmula:C25H26Cl2N6O6SPureza:99.42%Forma y color:SolidPeso molecular:609.48RU-302
CAS:<p>RU-302 is a pan inhibitor of TAM Receptor blocking the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain.</p>Fórmula:C24H24F3N3O2SPureza:99.84%Forma y color:SolidPeso molecular:475.53EAI001
CAS:<p>EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.</p>Fórmula:C19H15N3O2SPureza:>99.99%Forma y color:SolidPeso molecular:349.41Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64(E/Z)-CP-724714
CAS:<p>(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].</p>Fórmula:C27H27N5O3Pureza:98%Forma y color:SolidPeso molecular:469.54Limertinib
CAS:<p>Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.</p>Fórmula:C29H32ClN7O2Pureza:97.44%Forma y color:SolidPeso molecular:546.06AC710
CAS:<p>AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).</p>Fórmula:C31H42N6O4Pureza:99.67%Forma y color:SolidPeso molecular:562.7TC-S 7003
CAS:TC-S 7003 (Lck Inhibitor) is a Lck inhibitor with anti-inflammatory activity that inhibits T-cell proliferation and can be used to study arthritis.Fórmula:C31H30N8OPureza:99.74%Forma y color:SolidPeso molecular:530.62Bezuclastinib
CAS:<p>Bezuclastinib (CGT9486) is a novel, potent and highly selective tyrosine kinase and c-kit D816V inhibitor for the study of advanced mastocytosis.</p>Fórmula:C19H17N5OPureza:99.55%Forma y color:SolidPeso molecular:331.37Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Fórmula:C29H44N8O3C4H4O4Pureza:99.78%Forma y color:SolidPeso molecular:610.75Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Forma y color:SolidPeso molecular:389.45EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72Larotinib
CAS:<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Fórmula:C24H26ClFN4O4Pureza:98.45%Forma y color:SolidPeso molecular:488.94Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Fórmula:C40H38ClNO5Pureza:99.97%Forma y color:SolidPeso molecular:648.19Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Forma y color:Yellow Green Powder /Off-White SolidPeso molecular:202.17Pimicotinib
CAS:<p>Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.</p>Fórmula:C22H24N6O3Pureza:99.8%Forma y color:SolidPeso molecular:420.46ML 315
CAS:<p>ML 315 is a selective Clk and DYRK inhibitor with potential anticancer activity for the study of neurological disorders.</p>Fórmula:C18H13Cl2N3O2Pureza:99.08%Forma y color:SolidPeso molecular:374.22ProINDY
CAS:<p>ProINDY (Pro-indy) is a potent DYRK inhibitor that activates NFAT for the study of Down syndrome.</p>Fórmula:C14H15NO3SPureza:97.19%Forma y color:SolidPeso molecular:277.34PD 174265
CAS:<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Fórmula:C17H15BrN4OPureza:99.51%Forma y color:SolidPeso molecular:371.23GTP-14564
CAS:<p>GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3.</p>Fórmula:C15H10N2OPureza:99.69%Forma y color:SolidPeso molecular:234.25Epitinib succinate
CAS:<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Fórmula:C28H32N6O6Pureza:98.02% - 99.79%Forma y color:SolidPeso molecular:548.59Falnidamol
CAS:<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Fórmula:C18H19ClFN7Pureza:98.816%Forma y color:SolidPeso molecular:387.84A 419259 trihydrochloride
CAS:A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).Fórmula:C29H37Cl3N6OPureza:99.75% - 99.96%Forma y color:SolidPeso molecular:592CLK-IN-T3
CAS:<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Fórmula:C28H30N6O2Pureza:99.61%Forma y color:SolidPeso molecular:482.58EMI1
CAS:<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Fórmula:C20H18N2O3Pureza:99.96%Forma y color:SolidPeso molecular:334.37c-Fms-IN-13
CAS:<p>c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.</p>Fórmula:C22H26N4O2Pureza:99.93% - 99.97%Forma y color:SolidPeso molecular:378.47Chiauranib
CAS:<p>Chiauranib, a potent anticancer agent, inhibits angiogenesis kinases (VEGFR1-3, PDGFRα, c-Kit), Aurora B, and CSF1R with IC50 values of 1-9 nM.</p>Fórmula:C27H21N3O3Pureza:99.22%Forma y color:SolidPeso molecular:435.47A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Fórmula:C18H19F3N2O2Pureza:98.97% - 99.91%Forma y color:SolidPeso molecular:352.35VEGFR-3-IN-1
CAS:<p>VEGFR-3-IN-1, a potent VEGFR3 inhibitor (IC50=110.4 nM), hinders tumor growth and VEGFR3 signaling, affecting HDLEC and MDA-MB cell proliferation/migration.</p>Fórmula:C29H29ClF3N7OSPureza:99.95%Forma y color:SolidPeso molecular:616.1LY 456236 hydrochloride
CAS:<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Fórmula:C16H16ClN3O2Pureza:99.95%Forma y color:SolidPeso molecular:317.77EGFR-IN-99
CAS:<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Fórmula:C25H22FN7O3Pureza:97.75%Forma y color:SolidPeso molecular:487.49DDR Inhibitor
CAS:<p>DDR inhibitor is a potent discidin domain receptor (DDR) inhibitor. The IC50 of DDR2 is 3.3 nM, and DDR1 has 53% inhibition at 1.5 nM.</p>Fórmula:C23H20FN5O2Pureza:99.61%Forma y color:SolidPeso molecular:417.44RET-IN-3
CAS:<p>RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.</p>Fórmula:C18H21N5O2Pureza:99.52%Forma y color:SolidPeso molecular:339.39TG-89
CAS:<p>TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and</p>Fórmula:C26H34N6O3SPureza:98.68%Forma y color:SolidPeso molecular:510.65Pz-1
CAS:<p>Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.</p>Fórmula:C26H26N6O2Pureza:99.89%Forma y color:SolidPeso molecular:454.52PP58
CAS:<p>PP58 is an inhibitor of PDGFR, FGFR and Src family.</p>Fórmula:C22H19Cl2N5O2Pureza:99.21%Forma y color:SolidPeso molecular:456.32PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Fórmula:C20H18N4OPureza:99.2%Forma y color:SolidPeso molecular:330.38INDY
CAS:<p>INDY is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B with IC50s of 0.24 μM and 0.23 μM and a Ki of 0.18 μM for Dyrk1A ATP pocket, respectively.</p>Fórmula:C12H13NO2SPureza:99.26%Forma y color:SolidPeso molecular:235.3SU16f
CAS:<p>SU16f, a 3-substituted indolin-2-one, is a selective PDGFRβ inhibitor; IC50: 10 nM (PDGFRβ), 140 nM (PDGFR1), 2.29 μM (PDGFR2), halts GC cell growth.</p>Fórmula:C24H22N2O3Pureza:97.69%Forma y color:SolidPeso molecular:386.44I-OMe-Tyrphostin AG 538
CAS:<p>I-OMe-Tyrphostin AG 538: IGF-1R & PI5P4Kα inhibitor, ATP-competitive, IC50 of 1 µM, targets IGF-1R pathway, cytotoxic in nutrient-poor PANC1 cells.</p>Fórmula:C17H12INO5Pureza:98.23%Forma y color:SolidPeso molecular:437.19(Z)-FeCP-oxindole
CAS:<p>(Z)-FeCP-oxindole is a selective inhibitor of VEGFR2 with an IC50 of 200 nM for human. (Z)-FeCP-oxindole shows anticancer activity.</p>Fórmula:C19H15FeNOPureza:99.63% - 99.84%Forma y color:SolidPeso molecular:329.17LDN-211904 oxalate
CAS:<p>LDN-211904 oxalate (LDN211904 oxalate) is a selective and efficient EphB3 inhibitor with antitumor activity, useful in neurodegenerative disease research.</p>Fórmula:C21H21ClN4O5Pureza:99.87%Forma y color:SolidPeso molecular:444.87EGFR-IN-9
CAS:<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Fórmula:C29H24N4O3Pureza:99.8%Forma y color:SolidPeso molecular:476.53(R)-Zanubrutinib
CAS:<p>(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:99.55%Forma y color:SolidPeso molecular:471.55Tilfrinib
CAS:<p>Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.</p>Fórmula:C17H13N3OPureza:99.54%Forma y color:SolidPeso molecular:275.3SKLB 1028
CAS:<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Fórmula:C24H29N9Pureza:99.90% - >99.99%Forma y color:SolidPeso molecular:443.55YK-2-69
CAS:<p>YK-2-69 selectively blocks DYRK2 at Lys-231 and Lys-234, outperforming enzalutamide in prostate cancer treatment.</p>Fórmula:C25H27FN8OSPureza:98.61% - 99.64%Forma y color:SolidPeso molecular:506.6(E)-FeCP-oxindole
CAS:<p>(E)-FeCP-oxindole 是一种 VEGFR2 抑制剂，IC50 为 214 nM。</p>Fórmula:C19H15FeNOPureza:99.85%Forma y color:SolidPeso molecular:329.17AMPK-IN-3
CAS:<p>AMPK-IN-3: potent, selective AMPK (α2/α1) & KDR inhibitor; IC50: 60.7/107/3820 nM; anticancer in K562 cells.</p>Fórmula:C25H33N5O3Pureza:99.13%Forma y color:SolidPeso molecular:451.56CGP77675
CAS:<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Fórmula:C26H29N5O2Pureza:99.66%Forma y color:SolidPeso molecular:443.54(±)-Zanubrutinib
CAS:<p>(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,</p>Fórmula:C27H29N5O3Pureza:99.09%Forma y color:SolidPeso molecular:471.55CSF1R-IN-3
CAS:<p>CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM.</p>Fórmula:C30H38N8O4Pureza:97.31%Forma y color:SolidPeso molecular:574.67Sunvozertinib
CAS:<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Fórmula:C29H35ClFN7O3Pureza:98.11% - 99.63%Forma y color:SolidPeso molecular:584.08Rezivertinib
CAS:<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Fórmula:C27H30N6O3Pureza:99.26% - 99.89%Forma y color:SolidPeso molecular:486.57EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97AXL-IN-14
CAS:<p>AXL-IN-14: orally active, potent AXL inhibitor (IC50=0.8 nM); hinders Gas6/AXL migration, invasion; lowers p-AXL, p-AKT; anti-tumor.</p>Fórmula:C32H24F2N4O4Pureza:98%Forma y color:SolidPeso molecular:566.55Tyrphostin AG1433
CAS:<p>Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).</p>Fórmula:C16H14N2O2Pureza:98.47%Forma y color:SolidPeso molecular:266.29BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36AKB-6899
CAS:<p>AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated</p>Fórmula:C14H11FN2O4Pureza:97.87%Forma y color:SolidPeso molecular:290.25DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.562′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Forma y color:SolidPeso molecular:283.31Tyrosine kinase-IN-6
CAS:<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Fórmula:C37H31F2N5O5SPureza:98%Forma y color:SolidPeso molecular:695.73JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Forma y color:SolidPeso molecular:617.18EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Fórmula:C54H54Cl2FN7O7S2Pureza:98%Forma y color:SolidPeso molecular:1067.08EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Forma y color:SolidPeso molecular:514.58ENT-C225
CAS:<p>ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.</p>Fórmula:C26H40N4O5Pureza:99.36% - 99.36%Forma y color:SolidPeso molecular:488.62FGFR-IN-11
CAS:<p>FGFR-IN-11 (compound I-5) is an orally active, covalent inhibitor of FGFR, exhibiting IC50 values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (</p>Fórmula:C28H29ClN4O4Pureza:98%Forma y color:SolidPeso molecular:521.01Type II TRK inhibitor 1
CAS:<p>Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.</p>Fórmula:C35H33F3N8O3Pureza:98%Forma y color:SolidPeso molecular:670.68EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Fórmula:C26H30N8O2Pureza:98%Forma y color:SolidPeso molecular:486.57EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Fórmula:C33H37ClN8O3Pureza:98%Forma y color:SolidPeso molecular:629.15FGFR4-IN-8
CAS:<p>FGFR4-IN-8 is a selective, ATP-competitive FGFR4 inhibitor with IC50s as low as 0.25 nM, halting growth of Hep3B cells at 29 nM and showing in vivo efficacy.</p>Fórmula:C32H34Cl2FN7O3Pureza:98%Forma y color:SolidPeso molecular:654.56JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Forma y color:SolidPeso molecular:479.43TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Forma y color:SolidPeso molecular:512.43OTS447
CAS:<p>OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .</p>Fórmula:C27H32ClN3O2Pureza:98.78%Forma y color:SolidPeso molecular:466.02Vepafestinib
CAS:<p>Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].</p>Fórmula:C26H30N6O3Pureza:98.56%Forma y color:SolidPeso molecular:474.55UniPR505
CAS:<p>UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.</p>Fórmula:C39H57N3O5Pureza:98.23%Forma y color:SolidPeso molecular:647.89KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Forma y color:SolidPeso molecular:555.03Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Forma y color:SolidPeso molecular:389.4Axl/Mer/CSF1R-IN-2
CAS:<p>Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].</p>Fórmula:C24H22F3N5O5Forma y color:SolidPeso molecular:517.46EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SForma y color:SolidPeso molecular:729.57PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Fórmula:C19H22ClN7O3Pureza:98%Forma y color:SolidPeso molecular:431.88EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PForma y color:SolidPeso molecular:733.68EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PForma y color:SolidPeso molecular:610.49HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Forma y color:SolidPeso molecular:495.02MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Forma y color:SolidPeso molecular:901.42TL02-59
CAS:<p>TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.</p>Fórmula:C32H34F3N5O4Pureza:98.77%Forma y color:SolidPeso molecular:609.64FGFR3-IN-6
CAS:<p>FGFR3-IN-6 is a potent, selective inhibitor of FGFR 3, exhibiting an IC50 value of less than 350 nM , and is utilized in cancer research [1].</p>Fórmula:C25H23FN8O2Pureza:98%Forma y color:SolidPeso molecular:486.5EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Forma y color:SolidPeso molecular:538.64Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Fórmula:C20H16FN5O2Pureza:99.77%Forma y color:SolidPeso molecular:377.37c-Fms-IN-14
CAS:<p>c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].</p>Fórmula:C26H24N6OPureza:98%Forma y color:SolidPeso molecular:436.51AXL-IN-15
CAS:<p>AXL-IN-15 (cpd391) is a potent inhibitor of Axl, exhibiting both a dissociation constant (K i) and a half-maximal inhibitory concentration (IC50) of less than 1</p>Fórmula:C26H32F3N9O3Pureza:98%Forma y color:SolidPeso molecular:575.59UniPR1447
CAS:<p>UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].</p>Fórmula:C36H50N2O4Pureza:98%Forma y color:SolidPeso molecular:574.79BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Fórmula:C27H32N8O3Pureza:97.26%Forma y color:SolidPeso molecular:516.6EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Forma y color:SolidPeso molecular:266.29FGFR4-IN-16
CAS:<p>FGFR4-IN-16 (CY-15-2) is a covalent inhibitor targeting FGFR-4, utilized in cancer research [1].</p>Fórmula:C35H30Cl2N6O5Pureza:98%Forma y color:SolidPeso molecular:685.56BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Forma y color:SolidPeso molecular:354.2
